Patient‐reported neuropathic pain in adolescent and young adult cancer patients

Acquazzino, Melissa A.; Igler, Eva C.; Dasgupta, Mahua; Simpson, Pippa; Browning, Meghen B.; Brandow, Amanda M.

doi:10.1002/pbc.26364

Cited by 5 publications

(6 citation statements)

References 39 publications

(172 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies also addressed distinct sources of pain. Approximately 26% of adolescents receiving chemotherapy reported neuropathic pain—that is, pain occurring as a consequence of damage to the somatosensory nervous system (Acquazzino et al, 2017; International Association for the Study of Pain, 2018). Neuropathic pain was most frequently attributed to treatment (Anghelescu et al, 2014) and was not associated with the cumulative dose of vincristine (Anghelescu et al, 2011).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Symptoms in Children Receiving Treatment for Cancer—Part II: Pain, Sadness, and Symptom Clusters

Linder

Hooke

2019

J Pediatr Oncol Nurs

View full text Add to dashboard Cite

Children and adolescents receiving treatment for cancer experience multiple symptoms as a consequence of their disease and its treatment that interfere with the child’s quality of life. Understanding of symptom assessment in children with cancer is foundational to the work of the Children’s Oncology Group Nursing Discipline, whose research aims are to address knowledge gaps including understanding illness-related distress. This article is the second of a two-part summary of current evidence addressing the assessment of symptoms frequently reported by children and adolescents receiving treatment for cancer. Studies reporting assessment of pain, sadness, and symptom clusters published between January 2008 and May 2018 were included. Forty-three publications addressed pain. Pain was highly prevalent and distressing, varied in its trajectory across a cycle of chemotherapy and across multiple cycles of treatment, and correlated with biomarkers associated with the pain response. Consequences of pain were poorer functional status and emotional health. Twenty publications addressed sadness. Sadness was the most prevalent psychosocial symptom. Its prevalence decreased over the course of treatment and over a cycle of chemotherapy. Persistent sadness was of greater severity and distress. Eight publications addressed symptom clusters. These studies identified both groups of co-occurring symptoms and groups of patients with common symptom profiles. This two-article series provides evidence for the distressing nature of symptoms among children receiving cancer treatment. Efforts to support clinicians in routine symptom assessment are needed. Additional research directed at alleviating symptoms and building resilience among the child experiencing symptoms is needed.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Studies also provided evidence of biologic correlates of pain and specific sources of pain, including neuropathic pain, phantom limb pain, and procedural pain. Neuropathic pain, specifically, may be underrecognized and, therefore, undermanaged (Acquazzino et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Symptoms in Children Receiving Treatment for Cancer—Part II: Pain, Sadness, and Symptom Clusters

Linder

Hooke

2019

J Pediatr Oncol Nurs

View full text Add to dashboard Cite

show abstract

“…In addition, the PD-Q uses questions concerning the quality of pain to discriminate whether a subject is experiencing nociceptive pain or features suggestive of neuropathic-like pain. The PD-Q was developed to assess neuropathic pain in back pain ( 15 , 16 ) and has also been adapted and validated as a measure of central sensitization in the context of osteoarthritis ( 17 ). ( 18 , 19 ) Using the published scoring algorithm ( 15 ), which is based on 3 domains (sensory symptoms, pain course pattern, and pain radiation), participants were divided into 3 distinct groups: scores of 0 to 12 are indicative of nociceptive pain; scores of 13 to 18 are classed as unclear, where a neuropathic component may be present; and scores of 19 to 38 indicate neuropathic-like pain is likely.…”

Section: Methodsmentioning

confidence: 99%

Neuropathic-like Pain in Fibrous Dysplasia/McCune-Albright Syndrome

Spencer

Watts

Soni

et al. 2022

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Context Pain is a major symptom in adults with Fibrous dysplasia/McCune-Albright Syndrome (FD/MAS) and response to current treatments, including bisphosphonates and standard analgesics (NSAIDs and opiates) is unpredictable. No studies have explored whether the type of pain is variable in this patient group. Objective To determine the frequency of neuropathic-like pain in patients with FD/MAS. Design Retrospective, dual registry study Setting Community Patients FD/MAS online registries: the FD Foundation (FDF), USA based, and the Rare and Undiagnosed Diseases (RUDY) study (UK) Intervention Subjects completed questionnaires to evaluate the presence of features of neuropathic-like pain (painDETECT) and the impact sleep quality (Pittsburgh Sleep Quality Index) and mental health (Hospital Anxiety and Depression Scale). Descriptive statistics were used to characterize the prevalence and associated burden of neuropathic-like pain. Main Outcome Measures Incidence of neuropathic, nociceptive and unclear pain. Results Of 249 participants, one third experienced neuropathic-like pain. This group had statistically significantly (p<0.001) worse mental wellbeing and sleep in comparison to those with predominately nociceptive pain. Conclusions Neuropathic-like pain is common in patients with FD/MAS and associated with worse quality of life. Evaluation of pain in patients with FD/MAS should include assessment of neuropathic-like pain to guide personalized approaches to treatment and inform future research.

show abstract

“…A report of 10,012 survivors from the Childhood Cancer Survivor Study (CCSS) 38 showed that 29% of long‐term survivors of childhood cancer report moderate to severe pain, 20% report moderate to extreme pain interference, and 9% report moderate to severe recurrent pain. Although there has been far less research characterizing the nature of pain in young cancer survivors, one study 19 found that 11% of adolescent cancer survivors reports neuropathic pain. Central sensitization (an amplification of neural signaling within the central nervous system eliciting pain hypersensitivity) may be a contributory mechanism related to the occurrence and persistence of pain after childhood cancer 39,40 …”

Section: Introductionmentioning

confidence: 99%

“…4,[14][15][16] Several cancer treatment modalities can lead to nociceptive pain, for example as a consequence of cancer-related procedures. 17 Neuropathic pain ("pain due to a lesion or disease of the somatosensory nervous system" 18 ) is also common, 19 particularly as a consequence of radiation or chemotherapy. 20,21 Cancer-related pain can be persistent or experienced as "breakthrough pain," for example, as a consequence of infection at the level of the tumor, or drug interactions.…”

mentioning

confidence: 99%

Pain science education for children living with and beyond cancer: Challenges and research agenda

Rheel

Heathcote

Bosch³

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Pain in children living with and beyond cancer is understudied and undertreated. Pain science education (PSE) is a conceptual change strategy facilitating patients’ understanding of the biopsychosocial aspects of pain. Preliminary studies on the adaptation of PSE interventions to adults with and beyond cancer provide a foundation for pediatric research. PSE could help childhood cancer survivors experiencing persistent pain and pain‐related worry after active treatment. PSE may also help children receiving cancer treatment, providing them with a foundation of adaptive pain beliefs and cognitions, and preparing them for procedural and treatment‐related pain. We direct this paper toward pediatric oncology clinicians, policy makers, and researchers working with children living with and beyond cancer. We aim to (a) identify challenges in adapting PSE for children living with and beyond cancer, (b) offer possible solutions, and (c) propose research questions to guide the implementation of PSE for children living with and beyond cancer.

show abstract

Patient‐reported neuropathic pain in adolescent and young adult cancer patients

Abstract: Neuropathic pain occurs in one in four adolescents and young adults receiving cancer therapy. Use of screening tools may increase the detection of neuropathic pain in adolescents and young adults receiving cancer therapy and could ultimately improve pain treatment.

Cited by 5 publications

References 39 publications

Symptoms in Children Receiving Treatment for Cancer—Part II: Pain, Sadness, and Symptom Clusters

Symptoms in Children Receiving Treatment for Cancer—Part II: Pain, Sadness, and Symptom Clusters

Neuropathic-like Pain in Fibrous Dysplasia/McCune-Albright Syndrome

Pain science education for children living with and beyond cancer: Challenges and research agenda

Contact Info

Product

Resources

About